Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

Stock Information for Codexis Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Codexis Inc.

Codexis to Report First Quarter 2024 Financial Results on May 2
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Codexis to Participate in TD Cowen 44th Annual Health Care Conference
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones
seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.